The ability of TNJ to inhibit, but to not completely arrest or cause regression of neu-induced tumor growth, is consistent with the capabilities of other angiogenesis inhibitors, both in this model and in breast cancer patients [45, 46]. This evidence concerns the gene ERBB2 and neoplasm.